<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516646</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0527</org_study_id>
    <nct_id>NCT00516646</nct_id>
  </id_info>
  <brief_title>The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure</brief_title>
  <acronym>BENEFICIAL</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synvista Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synvista Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a
      role in the development and progression of heart failure. The AGE-crosslink breaker
      Alagebrium (ALT-711) improved cardiac function and symptoms in experimental and small human
      heart failure studies. These results have not yet been confirmed in a randomized controlled
      clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled, parallel design trial enrolling
      100 patients (2x50) with stable CHF. Patients will be randomized to either 200 mg Alagebrium
      twice daily or placebo for a period of 9 months. Efficacy measurements will be performed at
      baseline, and at the end of the study, and include aerobic capacity (VO2max) exercise
      testing, echocardiography, Minnesota Living with Heart Failure score, AGEs measurements in
      blood and skin, NYHA heart failure class, patient's and physician's global assessment, and
      levels of NT-pro-BNP. Safety visits are performed at 3 months intervals. In addition, one
      safety visit will be performed 2 weeks after the randomization visit and 1 month after the
      last treatment visit. A total of 8 visits will be performed during the entire study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point of the study will be aerobic capacity (VO2max) measured at exercise testing</measure>
    <time_frame>At baseline and after 9 months of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic function, diastolic function, advanced glycation end-products (AGE) measurements, changes in Minnesota Living with Heart Failure score, NYHA heart failure score, patient's and physician's global assessment, and NT-pro-BNP</measure>
    <time_frame>At baseline and after 9 months of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALT-711 200 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-711</intervention_name>
    <description>200 mg bid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alagebrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>bid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA II-IV heart failure

          -  Echocardiographic ejection fraction â‰¤ 40%

          -  Duration of heart failure &gt; 3 months

          -  Stable heart failure medical therapy for &gt; 1 months

        Exclusion Criteria:

          -  History of myocardial infarction in previous 6 months

          -  History of stroke in previous 6 months

          -  Clinically significant renal, liver, pulmonary,or hematological disease

          -  Active and or treated malignancies within 12 months

          -  Uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriaan A Voors, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Cardiology - University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <state>P.O. Box 30 001</state>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Thohan V, Koerner MM, Pratt CM, Torre GA. Improvements in Diastolic Function Among Patients with Advanced Systolic Heart Failure Utilizing Alagebrium (an Oral Advanced Glycation End-product Cross-link Breaker). American Heart Association Scientific Sessions . 2005. Ref Type: Abstract</citation>
  </reference>
  <reference>
    <citation>Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005 Apr;11(3):191-5.</citation>
    <PMID>15812746</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>A.A. Voors, MD PhD</name_title>
    <organization>University Medical Center Groningen, Groningen, The Netherlands</organization>
  </responsible_party>
  <keyword>Advanced Glycation End-products (AGEs)</keyword>
  <keyword>Alegebrium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

